Chonluten

Dosing from the Literature

Published for the airways: no trial dose; the Russian product information counts capsules and drops without saying how much peptide they hold. Not published: a randomized human trial.

No human dose comes from a trial published in a medical journal. The rows below come from the Russian product information and the developers' patent; none is an FDA-approved dose.

What It Is

Chonluten is a synthetic short peptide within the Khavinson bioregulator program. Its sequence is Glu-Asp-Gly (EDG), a tripeptide (a chain of 3 amino acids) with an approximate molecular weight of 319 daltons (Khavinson et al., US patent 8,071,556). Within the Khavinson framework, EDG is positioned as a respiratory-epithelium-directed bioregulator — a companion peptide to the tetrapeptide (a chain of 4 amino acids) Bronchogen (AEDL). The group's 2020 review calls both "bronchoprotectors" (Khavinson 2020, PMID 32987757).

Historically, the Khavinson program has a tradition of identifying multiple short peptides per tissue — with slightly different chain lengths and residue compositions — and claiming complementary tissue-directed activity. Chonluten (EDG) is the Khavinson tripeptide in this respiratory-bioregulator subgroup.

Note: Some community references and older Kalios content describe Chonluten as a gastrointestinal-mucosal bioregulator. Sources disagree on which mucosa it targets. The group's own papers point both ways. Its 2022 review lists Chonluten (EDG) as a "gastroprotector" and a "stress protector" (Khavinson 2022, PMID 35887081), and the group has tested EDG, under the code T-34, in rats with gastric ulcers (Khavinson 2012, Bull Exp Biol Med 152(5), PMID 22803148); a 2022 cell study with Khavinson as co-author describes Chonluten as "derived from bronchial epithelial cells" (Avolio 2022, PMID 35408963).

The biology of mucosal epithelium is informative context. The human airway epithelium is a complex pseudostratified columnar sheet comprising basal cells (progenitors), ciliated cells (mucociliary clearance), goblet cells (mucin secretion), and club cells (secretory defense). Most of the human airway is lined by this pseudostratified epithelium, in which basal cells, 6–30% of the cells, act as multipotent stem cells (Rock 2010, PMID 20699479). Tight-junction and adherens-junction complexes maintain the selective barrier that separates inhaled air — with its pollutants, pathogens, and allergens — from the sub-epithelial immune system. Dysfunction of this barrier is implicated in asthma, COPD, bronchiectasis, chronic rhinosinusitis, and respiratory long-COVID. Similarly, the gastrointestinal epithelial barrier, with its own tight-junction machinery and mucin layer, is implicated in IBD, celiac disease, and various systemic inflammatory conditions under the broad heading of "intestinal permeability" or "leaky gut." Against this backdrop, a short peptide that reportedly supports tight-junction assembly and barrier integrity would, in principle, be of interest — but the gap between "in principle interesting preclinical activity" and "clinically validated therapy" is exactly what the Chonluten evidence base does not bridge.

Commercially, Chonluten is distributed as an oral capsule within the Khavinson dietary-supplement line and as a lyophilized research peptide, which sellers list in 20 mg vials. Neither form is a registered pharmaceutical. In Russia it is sold as a BAD; outside Russia it is research-only. It is not used or recognized by mainstream pulmonology or gastroenterology.

Who Khavinson was, and what his record supports →

Mechanism of Action

The Khavinson framework proposes that short bioregulator peptides act as sequence-specific DNA-binding molecules modulating promoter activity at tissue-specific gene sets (Khavinson 2021, PMID 34834147). Chonluten's mechanism is described within this epigenetic-bioregulator framework. Independent mechanism validation outside the originating program is limited.

• Bronchial epithelial differentiation (proposed) — Khavinson/Linkova 2012 (PMID 22808515) and related publications describe tissue-specific short peptides promoting differentiation markers in aged cell cultures; no study of EDG in bronchial-epithelial differentiation was found (the 2012 paper tested bronchogen, pancragen and vesugen).
• Tight-junction and barrier reinforcement (unsupported) — No study of EDG and tight-junction proteins (claudins, occludin, ZO-1) or barrier function was found in PubMed or Europe PMC.
• Mucociliary function (unsupported for EDG) — The mucin-gene (MUC5AC) finding belongs to Bronchogen (AEDL), not EDG (Khavinson 2020, PMID 32987757); no study of EDG and mucin or cilia genes was found.
• Anti-inflammatory / cytokine modulation — In human THP-1 macrophages (a leukemia-derived immune-cell line, not mucosal epithelium) stimulated with bacterial lipopolysaccharide, Chonluten lowered the release of TNF-α (a major inflammatory signaling molecule) and IL-6 (a pro-inflammatory cytokine tied to chronic inflammation), as the four other Khavinson peptides tested did (Avolio 2022, PMID 35408963). No EDG study in mucosal-epithelium cultures or of IL-1β was found.
• Antioxidant defense — No study of EDG and SOD, catalase or glutathione peroxidase in epithelial cultures was found. The antioxidant data for EDG itself come from rat stomach, not airway cultures: in rats with gastric ulcers, EDG (coded T-34) is reported to normalize the synthesis of antioxidant and anti-inflammatory proteins by regulating their genes (Khavinson 2012, PMID 22803148).
• DNA / chromatin interaction (proposed) — Fedoreyeva 2011 (PMID 22117547) showed nuclear penetration of labeled epithalon, pinealon and testagen (EDG was not tested); the group's 2021 review proposes that short peptides in general bind DNA (Khavinson 2021, PMID 34834147), but no DNA-binding study of EDG was found.
• Immune / cytokine axis — Gumen 2006 (PMID 17426849) macrophage lymphocyte-activating-factor data describe broader immunomodulation under other short Khavinson peptides (Vilon, Epithalon and Cortagen); EDG was not tested.
• Short-residue composition context — EDG contains two acidic residues (Glu, Asp) and a small neutral residue (Gly). In the group's 2023 computer-docking study, EDG ranked second of 26 short peptides for binding a model of the LAT1 amino-acid transporter; the authors say such peptides could be carried by these transporters or could block them, and no uptake was measured (Khavinson 2023, PMID 36979488).
• Goblet-cell and mucin biology — Goblet-cell hyperplasia and metaplasia are among the airway changes in COPD, asthma and cystic fibrosis (Rock 2010, PMID 20699479); no study of EDG and goblet cells or mucin secretion was found.
• Ciliated-cell differentiation markers — FOXJ1, RFX3, and related transcription factors drive ciliated-cell differentiation from basal progenitors (Didon 2013, PMID 23822649). No study of EDG and these markers was found.
• Secretory-IgA / BALT modulation — The bronchus-associated lymphoid tissue (BALT) is a key component of respiratory mucosal immunity (Bienenstock 2005, PMID 16048540). No study of EDG and BALT or secretory IgA was found.

Limitation: the mechanism is a hypothesis of one research program — every EDG paper cited here has Khavinson or his institute among its authors — and no DNA-footprinting, ChIP-seq or gene-target mapping study of EDG was found.

What the Research Shows

The papers found on Chonluten — two cell studies, a rat study, a computer-docking study and two reviews — all come from Khavinson's group or list him as a co-author; they appeared in Bulletin of Experimental Biology and Medicine, the English edition of a Russian journal, and in MDPI journals. Evidence is mostly preclinical; the one human test found is in the developers' patent (Khavinson et al., US patent 8,071,556). No randomized controlled human trials.

• Tissue-specific differentiation (Khavinson/Linkova 2012, PMID 22808515) — Short peptides tissue-specifically stimulated cell differentiation in aged cultures; the paper tested pancragen, bronchogen and vesugen, not EDG.
• Program-level gene regulation review (Khavinson 2021, PMID 34834147) — Systematic review of the group's short-peptide gene-regulation work; it does not mention EDG or Chonluten.
• Nuclear penetration (Fedoreyeva 2011, PMID 22117547) — Labeled epithalon, pinealon and testagen reached the nuclei of HeLa cells; EDG was not tested.
• Immune/cytokine (Gumen 2006, PMID 17426849) — Short Khavinson peptides modulate macrophage cytokine production in aging.
• Linkova aging fibroblast (a cell that builds collagen) paradigm (2016, PMID 27259496) — Tested KE, KED, AED and AEDG in aging skin fibroblasts; EDG was not tested, so this is method context only.
• Human monocytes and macrophages (Avolio 2022, PMID 35408963) — In a cell-line study by an Italian–Russian team with Khavinson as co-author, Chonluten (the tripeptide Glu-Asp-Gly) at 100 ng/mL lowered the TNF and IL-6 released by THP-1 macrophages stimulated with bacterial lipopolysaccharide, as all five Khavinson peptides tested did, and made THP-1 monocytes stick less to endothelial cells activated with lipopolysaccharide. It was also the only one of the five to raise apoptosis in the monocytes, to about twice the level seen with the others.
• Skin explants (Voicekhovskaya 2012, PMID 22803085) — In skin explants from young rats, EDG (coded T-34) was the only one of five tripeptides tested that did not stimulate cell proliferation; for explants from old rats, the abstract reports a marked effect for the tripeptide KED. A study from Khavinson's institute.
• Mucosal epithelial cell culture — No study of EDG in respiratory or gastrointestinal epithelial cells (barrier function, transepithelial resistance, tight junctions) was found; the EDG cell studies found are in immune cells (Avolio 2022) and rat skin explants (Voicekhovskaya 2012).
• Rodent study — In rats with gastric ulcers, EDG (coded T-34) is reported to normalize the synthesis of antioxidant and anti-inflammatory proteins by regulating their genes (Khavinson 2012, PMID 22803148); no aged-animal study of EDG was found.
• No human RCTs — No double-blind placebo-controlled trials of EDG for respiratory disease, gastrointestinal disease, or any other endpoint exist in English-indexed peer-reviewed journals.
• No pulmonology / gastroenterology society recognition — ATS, ERS, GOLD, AGA, and ACG do not mention Chonluten in guidance documents.

Human Data

Synthetic Chonluten (EDG) has not been evaluated in published randomized controlled human trials. Accessible human-use information:

• Parent-extract Soviet-era observational use — Earlier Russian pulmonology and gastroenterology observational reports on related polypeptide tissue extracts describe symptom reports. These predate modern trial methodology and apply to crude extracts, not the defined EDG tripeptide.
• Supplement-line post-market experience — Observational reports from the Khavinson bioregulator product line. Not controlled clinical evidence. A 2020 review by Khavinson's group states that oral EDG and AEDL are effective in chronic obstructive pulmonary disease and in chronic bronchitis with an asthmatic component, and that EDG improved the results of standard therapy in patients with asthmatic chronic bronchitis, but that passage cites no human study (Khavinson 2020, Molecules, PMID 32987757).
• Developers' patent study — In the developers' patent, 60 healthy men aged 20–22 were given the peptide as nose drops or injections into muscle for 2 days (1 μg, 100 μg or 5 mg a dose) and 20 were given a placebo, before an hour in a pressure chamber at a simulated altitude of 5,000 m. The patent reports that 80–90% of the peptide groups tolerated the low-oxygen test well, against 60% on placebo, with a smaller rise in heart rate. It describes no randomization or blinding, and no journal report of the study was found (Khavinson et al., US patent 8,071,556).
• No human PK/PD — No published human pharmacokinetic or pharmacodynamic data for EDG.
• No WADA-relevant data — No effect on exercise performance or anti-doping-relevant endpoints documented.
• No specialty-society recognition — Pulmonology (ATS, ERS, GOLD) and gastroenterology (AGA, ACG) guidelines do not include Chonluten.

As with Cartalax and other Khavinson short peptides, the absence of human RCT data is the central evidentiary fact. The Khavinson-framework scientific case rests on preclinical mechanism demonstrations (cell culture, aged-animal models) and an epigenetic-bioregulator hypothesis. The translation from those data to clinical benefit in any human respiratory or gastrointestinal disease is unvalidated. Users who have found observational, clinical, or self-experimentation benefit cannot rule out placebo, concurrent standard-of-care, or regression-to-mean effects.

Mucosal-Immunity Context

To the extent Chonluten has a biologically coherent positioning, it sits within the broader framework of the common mucosal immune system — the recognition that respiratory, gastrointestinal, genitourinary and mammary mucosal surfaces share IgA-producing immune cells that travel between them, secretory IgA / IgM machinery, and tolerogenic/immunoregulatory circuits. The concept grew from mouse experiments in which dividing B cells from the gut's lymph nodes homed to the gut, genital tract and mammary glands, and those from the bronchial lymph nodes mainly to the lungs, most of them carrying IgA (McDermott 1979, PMID 448111). A peptide with even modest effects on epithelial differentiation, tight-junction protein expression, or mucin-gene activity could in principle have cross-compartment effects. This framing is more mainstream than some other aspects of the Khavinson program and is consistent with the broader literature on secretory-IgA physiology, gut-lung axis, mucosal dendritic cell cross-compartment trafficking, and microbiota-immunity interactions.

The practical limitation, however, is that "could in principle" and "demonstrated to do so" are different claims. No published study documents Chonluten-induced changes in secretory IgA output, tight-junction protein abundance on human biopsy, transepithelial electrical resistance in organoid models from primary human tissue, or common-mucosal-system functional endpoints. The Khavinson-program cell-culture data are interesting but not sufficient to establish that AEDL or EDG cross-modulate the common mucosal system in humans.

Reconstitution & Storage

Research-chemical sellers list Chonluten as lyophilized powder in 20 mg vials. In Russia it is sold as a dietary supplement in 0.2 g capsules, 0.16 g and 0.3 g tablets and a sublingual liquid (Russian product labeling).

• Reconstitution — Reconstitution guides describe swirling gently rather than shaking.
• Storage (research powder) — One seller lists a shelf life of 36 months; none of the four seller pages read gives a storage temperature or a time limit after mixing.
• Storage (Russian supplement) — Capsules and tablets: dry, away from light, at 2–25°C, for 5 years; the sublingual liquid: away from direct sunlight, at 2–25°C, for 3 years (Russian product labeling).

→ Calculator — vial-to-syringe math

Side Effects & Risks

• Tolerability — No published report on side effects in people was found; the Khavinson institute's product page says none have been found with its Cytogen capsules, Chonluten among them.
• Developers' animal tests — The developers' patent reports no toxic reactions after single injections of up to 5 mg/kg in mice, and no side effects from daily injections of up to 1 mg/kg for 90 days in rats and 6 months in guinea pigs, though the guinea pigs' white-cell counts rose at 3 months and were back to normal by 6 (Khavinson et al., US patent 8,071,556). No reproductive or genotoxicity study was found.
• Not a bronchodilator or an asthma, COPD or stomach drug — No published study was found that tested it as a treatment in people with lung or stomach disease, and Russia registers it as a dietary supplement, not a medicine (Russian product labeling).
• Purity / source — The vials sold outside Russia are research chemicals, which are not held to drug-quality standards.
• Pregnancy / lactation / pediatric — Russian product labeling lists pregnancy and breastfeeding as contraindications; no study in pregnancy, breastfeeding or children was found.
• WADA status — Not specifically named on the 2026 WADA Prohibited List.
• Theoretical epigenetic concerns — The developers report that EDG changes the activity of genes such as c-Fos and HSP70 in rats (Khavinson 2012, PMID 22803148; Khavinson et al., US patent 8,071,556); the long-term effects of such changes have not been studied in people, so any off-target risk is theoretical.

Bloodwork & Monitoring

No trial, label or guideline sets monitoring for Chonluten. The one human study found, in the developers' patent, measured anxiety and mood scores, heart rate, blood pressure, physical working capacity and oxygen uptake in healthy young men around a low-oxygen test (Khavinson et al., US patent 8,071,556).

Commonly Stacked With

The Khavinson institute's product page lists combined schemes for its own capsules: Chonluten with Crystagen and Vesugen for the respiratory system, and with Vesugen and Ovagen after radiation or chemotherapy, stress and other extreme exposures. No study found tested these combinations, and no study or seller listing found pairs Chonluten with BPC-157, Thymalin, LL-37 or Epithalon.

Stacking this? Read the receipt →

→ Calculator — vial-to-syringe math

Legal Status

Related Compounds

People researching Chonluten often also look at these:

Next Steps

References

1. Khavinson VKh, Linkova NS, Polyakova VO, Kheifets OV, Tarnovskaya SI, Kvetnoy IM. Peptides tissue-specifically stimulate cell differentiation during their aging. Bulletin of Experimental Biology and Medicine. 2012;153(1):148-151. PMID: 22808515.
2. Khavinson VKh, Popovich IG, Linkova NS, Mironova ES, Ilina AR. Peptide Regulation of Gene Expression: A Systematic Review. Molecules. 2021;26(22):7053. PMID: 34834147.
3. Fedoreyeva LI, Kireev II, Khavinson VKh, Vanyushin BF. Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA. Biochemistry (Moscow). 2011;76(11):1210-1219. PMID: 22117547.
4. Gumen AV, Kozinets IA, Shanin SN, Malinin VV, Rybakina EG. Production of lymphocyte-activating factors by mouse macrophages during aging and under the effect of short peptides. Bulletin of Experimental Biology and Medicine. 2006;142(3):360-362. PMID: 17426849.
5. Lin'kova NS, Drobintseva AO, Orlova OA, Kuznetsova EP, Polyakova VO, Kvetnoy IM, Khavinson VKh. Peptide Regulation of Skin Fibroblast Functions during Their Aging In Vitro. Bulletin of Experimental Biology and Medicine. 2016;161(1):175-178. PMID: 27259496.
6. FDA. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the FD&C Act (503A categories list), versions updated April 15, April 22 and May 14, 2026. fda.gov/media/94155/download. Read October 3, 2026. (Notice that 12 peptides would leave Category 2 because their nominations were withdrawn; their removal; GHK-Cu, except injectable, back in Category 1.)
7. Khavinson V, Linkova N, Kozhevnikova E, Dyatlova A, Petukhov M. Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences. 2022;23(14):7733. PMID: 35887081.
8. Khavinson VKh, Lin'kova NS, Dudkov AV, Polyakova VO, Kvetnoi IM. Peptidergic regulation of expression of genes encoding antioxidant and anti-inflammatory proteins. Bulletin of Experimental Biology and Medicine. 2012;152(5):615-618. PMID: 22803148.
9. Avolio F, Martinotti S, Khavinson VK, Esposito JE, Giambuzzi G, Marino A, et al. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line. International Journal of Molecular Sciences. 2022;23(7):3607. PMID: 35408963.
10. Khavinson VK, Linkova NS, Rudskoy AI, Petukhov MG. Feasibility of Transport of 26 Biologically Active Ultrashort Peptides via LAT and PEPT Family Transporters. Biomolecules. 2023;13(3):552. PMID: 36979488.
11. Voicekhovskaya MA, Chalisova NI, Kontsevaya EA, Ryzhak GA. Effect of bioregulatory tripeptides on the culture of skin cells from young and old rats. Bulletin of Experimental Biology and Medicine. 2012;152(3):357-359. PMID: 22803085.
12. Khavinson V, Linkova N, Dyatlova A, Kuznik B, Umnov R. Peptides: Prospects for Use in the Treatment of COVID-19. Molecules. 2020;25(19):4389. PMID: 32987757.
13. Rock JR, Randell SH, Hogan BL. Airway basal stem cells: a perspective on their roles in epithelial homeostasis and remodeling. Disease Models & Mechanisms. 2010;3(9-10):545-556. PMID: 20699479.
14. Didon L, Zwick RK, Chao IW, Walters MS, Wang R, Hackett NR, Crystal RG. RFX3 modulation of FOXJ1 regulation of cilia genes in the human airway epithelium. Respiratory Research. 2013;14(1):70. PMID: 23822649.
15. Bienenstock J, McDermott MR. Bronchus- and nasal-associated lymphoid tissues. Immunological Reviews. 2005;206:22-31. PMID: 16048540.
16. McDermott MR, Bienenstock J. Evidence for a common mucosal immunologic system. I. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. Journal of Immunology. 1979;122(5):1892-1898. PMID: 448111.
17. Khavinson VKh, Grigoriev EI, Malinin VV, Ryzhak GA. Peptide substance revealing a stress protective effect, pharmaceutical composition on its base, and the method of its application. US patent 8,071,556 B2; December 6, 2011 (filed March 5, 2007). Russian original: RU 2304444 C1; August 20, 2007 (filed May 23, 2006). patents.google.com/patent/US8071556B2. Read October 4, 2026. (The developers' patent on the tripeptide H-Glu-Asp-Gly-OH.)
18. St. Petersburg Institute of Bioregulation and Gerontology. [Cytogens] and [How to take], product pages. old.gerontology.ru/pills/cytogens/ and old.gerontology.ru/pills/intake/. Read October 4, 2026. (In Russian; lists Chonluten's state registration certificate, No. 77.99.23.3.У.9175.8.06, and gives one dosing scheme for all its Cytogen and Cytomax capsules.)
19. RLS (Register of Medicines of Russia). [Chonluten] and [Chonluten lingual]: registration data of the biologically active supplements. rlsnet.ru/baa/xonluten-30385 and rlsnet.ru/baa/xonluten-lingval-66641. Updated August 8, 2022. Read October 4, 2026. (In Russian; capsules 0.2 g, tablets 0.16 g and 0.3 g, and a sublingual liquid.)
20. World Anti-Doping Agency. Prohibited List 2026 (in effect January 1, 2026). S0, Non-approved substances. wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf. Read October 3, 2026.

Related Research

• BronchogenKhavinson Bronchial Bioregulator
• CardiogenKhavinson Cardiac Bioregulator
• EpithalonPineal Tetrapeptide / Khavinson Bioregulator
• OvagenKhavinson Tripeptide Bioregulator (Hepato-GI)
• FDA TrackerPCAC voted on 7 of the 12 peptides on July 23–24, 2026; FDA plans a PCAC review of the other 5 before the end of February 2027.